A Phase 3 interventional study of adalimumab in Crohn's Disease, sponsored by Abbott. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-11-20.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.
Among the 42 studies testing adalimumab in Crohn Disease, this one is the 6th largest by enrollment, is one of 4 that started in 2007, is one of 22 in phase 3, and was the 10th registered.
1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 6–17
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18–70
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 24 · Phase 4 13
First in 2002; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 304 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 143 across the 42 interventional studies. Of the 32 that completed or were terminated, 19 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 42 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
17 studies in Crohn Disease by Abbott: none open now, none under way, none of them phase 3. Of 17 finished, 9 (53%) have results posted.
Among the 17 studies in Crohn Disease by Abbott, this one is the 5th largest by enrollment, is one of 5 that started in 2007, is one of 10 in phase 3, and was the 13th registered.
Abbott’s Crohn Disease studies by the year they started, since 2002.
1 of the studies testing adalimumab in Crohn Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies testing adalimumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 17 in Crohn Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To make adalimumab available to subjects suffering from moderately to severely active Crohn's Disease (CD) and to expand the safety information on adalimumab. The study also assessed changes in Patient Reported Outcome Measures from baseline.
This was a Phase 3, multicenter, open-label, Early Access Study with an induction regimen of adalimumab 160 mg subcutaneous (SC) at Baseline and 80 mg SC at Week 2, followed by maintenance dosing of 40 mg every other week (eow) starting at Week 4 in subjects with moderately to severely active Crohn's Disease (CD) who were eligible to receive biologic therapy or who had failed to respond to, lost response to, or were intolerant to infliximab. Failure of prior therapy was determined by the Investigator. Subjects were to have an 8-week wash-out period prior to Baseline from the last dose of infliximab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open Label
Biological: adalimumab
160 mg loading dose, 80 mg at week 2, 40 mg every other week
Also known as: ABT-D2E7, Humira
Mean Extent of Exposure - Duration in Days
Extent of exposure for all adalimumab treated subjects
Time frame: Up to 24 weeks
Total Number of Injections of Adalimumab
Extent of exposure for all adalimumab treated subjects
Time frame: Up to 24 weeks
Compliance With Number of Injections of Adalimumab. Compliance Corresponds to Patients Who Received Their Injections.
Treatment compliance (%) = 100 \* (Number of doses of study medication actually received)/(Number of doses planned during the subject's participation in the study).
Time frame: Up to 24 weeks
Fistula Count Mean Change From Baseline (Change in Number of Fistulas From Baseline).
Draining fistula counts is the sum of abdominal and perianal fistulas for each subject at each visit.
Time frame: Week 12, Week 24, and Last Assessment Value (last nonmissing value)
Overall Health Care Resource Utilization
From the "Overall Health Care Resource Utilization Questionnaire": Number visits to physician, number visits to Emergency Room, number of hospital admissions, number of days of hospitalization.
Time frame: Up to 24 weeks
Employment Status: Number of Subjects Employed
Summary of employment status of those employed.
Time frame: Baseline, Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)
50% Improvement in Draining Fistula Count and Fistula Healing
Decrease in draining fistula is beneficial. "50 percent improvement" refers to a reduction in the number of baseline fistula by 50 percent.
Time frame: Week 12, Week 24, Last Assessment Value (last nonmissing value)
Work Productivity and Activity Impairment - Change From Baseline in Overall Work Impairment
Scores are expressed as impairment percentages, higher numbers indicate greater impairment and less productivity (0% = no impairment; 100% = total loss of work productivity). Minimal clinically important difference = 7 points. Measure is Mean percent change.
Time frame: Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)
Hematology - Change From Baseline to Final Visit
Changes from the Group mean at baseline are compared to the final visit Group mean value
Time frame: Up to 24 weeks
Clinical Chemistry - Change From Baseline to Final Visit
Changes from the Group mean at Baseline are compared to the final visit Group mean value
Time frame: Up to 24 weeks
Urinalysis - Change From Baseline to Final Visit
Changes from the Group mean at baseline are compared to the final visit Group mean value
Time frame: Up to 24 weeks
Work Productivity and Activity Impairment - Change From Baseline in Absenteeism
The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.
Time frame: Weeks 4, 8, 12, and 24, and Last Assessmentl Value (last nonmissing value)
Work Productivity and Activity Impairment - Change From Baseline in Presenteeism
The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.
Time frame: Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)
Work Productivity and Activity Impairment - Change From Baseline in Activity Impairment
The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.
Time frame: Weeks 4, 8, 12, and 24, and Last Assessment Value (last nonmissing value)
| Milestone | 40 mg Adalimumab Every Other Week |
|---|---|
| Started | 304 |
| Completed | 254 |
| Not completed | 50 |
| Withdrew: Adverse event | 26 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Other reason not specified | 10 |
| Withdrew: Adverse event + hospitalization | 1 |
| Withdrew: Adverse event + withdrew consent | 1 |
| Withdrew: Adverse event + no response | 1 |
| Withdrew: Adverse event + worsening of cd | 1 |
| Withdrew: Adverse event + no therapeutic benefit | 1 |
| Withdrew: Adverse event + lost response | 1 |
| Withdrew: Adverse event + withdrawn from study | 1 |
| Withdrew: Withdrew consent + lack of efficacy | 1 |
Extent of exposure for all adalimumab treated subjects
| days | 40 mg Adalimumab Every Other Week |
|---|---|
| Mean Extent of Exposure - Duration in Days | 159.2 ± 34.78 |
HBI score (range 0-30) sum subtotal of 5 parameters of subject's CD activity: a)Well being 0=very well-4=terrible b) Abdominal pain 0=none- 3=severe c) Number liquid stools per day d) Abdominal mass 0=none-3=tender e) Complications: 1 point each. Decrease indicates improvement. Absolute decrease of 3 units on scale is clinically important.
| Units on scale | 40 mg Adalimumab Every Other Week |
|---|---|
| Week 4 | -4.39 (-4.94 to -3.84) |
| Week 8 | -4.53 ± 5.175 |
| Week 12 | -5.32 ± 5.008 |
| Week 24 | -6.36 ± 5.031 |
| Last Assessment Value | -5.92 ± 5.162 |
Draining fistula counts is the sum of abdominal and perianal fistulas for each subject at each visit.
| number of fistulas | 40 mg Adalimumab Every Other Week |
|---|---|
| Week 12 | -0.17 ± 0.644 |
| Week 24 | -0.15 ± 0.587 |
| Last Assessment Value | -0.15 ± 0.567 |
Extent of exposure for all adalimumab treated subjects
| injections | 40 mg Adalimumab Every Other Week |
|---|---|
| Number of Injections During Induction Therapy | 2 ± 0.1 |
| Number of Injections During Maintenance Therapy | 11.8 ± 4.24 |
Treatment compliance (%) = 100 \* (Number of doses of study medication actually received)/(Number of doses planned during the subject's participation in the study).
| Percentage of injections | 40 mg Adalimumab Every Other Week |
|---|---|
| Compliance With Number of Injections of Adalimumab. Compliance Corresponds to Patients Who Received Their Injections. | 98.85 ± 4.207 |
Quality of life questionnaire for patients with IBD consisting of 4 domains: systemic, social, emotional, and bowel. This is a 10-item questionnaire, and all items are reported with a 7-point scale (ranging from 1 = poor HRQOL, to 7 = optimum HRQOL). Total SIBDQ score ranges from 10 (quality of life has been negatively affected tremendously by IBD) to 70 (quality of life is barely impacted by IBD). A change greater than 9 points was the minimal clinically important difference (MCID).
| units on a scale | 40 mg Adalimumab Every Other Week |
|---|---|
| Week 4 | 10.16 ± 10.692 |
| Week 8 | 11.85 ± 11.591 |
| Week 12 | 13.14 ± 11.783 |
| Week 24 | 15.06 ± 12.209 |
| Last Assessment Value | 13.74 ± 12.629 |
From the "Overall Health Care Resource Utilization Questionnaire": Number visits to physician, number visits to Emergency Room, number of hospital admissions, number of days of hospitalization.
| number of visits | 40 mg Adalimumab Every Other Week |
|---|---|
| Number of visits to a physician | 1.13 ± 2.794 |
| Number of visits to Emergency Room | 0.17 ± 0.522 |
| Number of hospital admissions | 0.10 ± 0.346 |
| Number of days of hospitalizations | 0.60 ± 2.790 |
Summary of employment status of those employed.
| participants | 40 mg Adalimumab Every Other Week |
|---|---|
| Baseline | 195 ± 64.1 |
| Week 4 | 199 |
| Week 8 | 198 |
| Week 12 | 192 |
| Week 24 | 190 |
| Last Assessment Value | 208 |
Decrease in draining fistula is beneficial. "50 percent improvement" refers to a reduction in the number of baseline fistula by 50 percent.
| participants | 40 mg Adalimumab Every Other Week |
|---|---|
| Week 12 50% Improvement in draining fistula | 35 |
| Week 24 50% Improvement in draining fistula | 31 |
| Last Value 50% Improvement in draining fistula | 32 |
| Week 12 Fistula Healing | 23 |
| Week 24 Fistula Healing | 27 |
| Last Assessment Value Fistula Healing | 28 |
Scores are expressed as impairment percentages, higher numbers indicate greater impairment and less productivity (0% = no impairment; 100% = total loss of work productivity). Minimal clinically important difference = 7 points. Measure is Mean percent change.
| Units on scale | 40 mg Adalimumab Every Other Week |
|---|---|
| Week 4 | -22.08 ± 28.454 |
| Week 8 | -22.36 ± 29.337 |
| Week 12 | -29.93 ± 33.669 |
| Week 24 | -31.23 ± 30.403 |
| Last Assessment Value | -28.49 ± 32.286 |
Changes from the Group mean at baseline are compared to the final visit Group mean value
| number | 40 mg Adalimumab Every Other Week |
|---|---|
| Hemoglobin (g/L) | 2.2 ± 12.43 |
| Hematocrit (fraction) | 0.011 ± 0.0376 |
| Red blood cell count (x10^9/L) | 0.03 ± 0.353 |
| Platelet Count (x10^9/L) | -30.2 ± 89.28 |
| White blood cell count (x10^9/L) | -1.59 ± 3.297 |
| Neutrophils (x10^9/L) | -2.005 ± 3.1777 |
| Lymphocytes (x10^9/L) | 0.408 ± 0.7285 |
| Monocytes (x10^9/L) | -0.014 ± 0.1725 |
| Eosinophils (x10^9/L) | 0.009 ± 0.1505 |
| Basophils (x10^9/L) | -0.015 ± 0.0617 |
Changes from the Group mean at Baseline are compared to the final visit Group mean value
| number | 40 mg Adalimumab Every Other Week |
|---|---|
| SGPT/ALT (U/L) | 0.6 ± 17.89 |
| SGOT/ALT (U/L) | 1.6 ± 10.35 |
| Alkaline phosphatase (U/L) | -5.2 ± 21.53 |
| Total Bilirubin (mcmol/L) | 1.6 ± 4.06 |
| Creatinine (mcmol/L) | 1.7 ± 10.35 |
| BUN (mmol/L) | 0.06 ± 1.367 |
| Uric acid (mcmol/L) | 4.6 ± 52.38 |
| Inorganic phosphate | 0.016 ± 0.2588 |
| Calcium (mmol/L) | 0.008 ± 0.1189 |
| Sodium (mmol/L) | -0.3 ± 2.38 |
| Potassium (mmol/L) | -0.00 ± 0.779 |
| Albumin (G/L) | 0.4 ± 4.01 |
| Total protein (G/L) | 0.8 ± 4.83 |
| Cholesterol (mmol/L) | 0.021 ± 0.7024 |
| Triglycerides (mmol/L) | 0.093 ± 0.7581 |
| C-reactive protein (mg/L) | -8.181 ± 28.7023 |
| Glucose - fasting (mmol/L) | -0.268 ± 1.3893 |
Changes from the Group mean at baseline are compared to the final visit Group mean value
| number | 40 mg Adalimumab Every Other Week |
|---|---|
| Urine pH | 0.02 ± 0.980 |
| Specific gravity | -0.0004 ± 0.00713 |
The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.
| units on a scale | 40 mg Adalimumab Every Other Week |
|---|---|
| Week 4 | -5.99 ± 24.592 |
| Week 8 | -7.55 ± 27.543 |
| Week 12 | -8.74 ± 33.477 |
| Week 24 | -8.54 ± 27.260 |
| Last Assessment Value | -6.46 ± 29.167 |
The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.
| Units on scale | 40 mg Adalimumab Every Other Week |
|---|---|
| Week 4 | -20.58 ± 26.115 |
| Week 8 | -19.94 ± 27.151 |
| Week 12 | -25.79 ± 30.113 |
| Week 24 | -28.96 ± 28.472 |
| Last Assessment Value | -26.69 ± 30.058 |
The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.
| Units on scale | 40 mg Adalimumab Every Other Week |
|---|---|
| Week 4 | -23.59 ± 26.928 |
| Week 8 | -24.79 ± 28.431 |
| Week 12 | -30.36 ± 28.697 |
| Week 24 | -34.00 ± 29.552 |
| Last Assessment Value | -30.98 ± 30.484 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 40 mg Adalimumab Every Other Week | — | — | — |
| Event | 40 mg Adalimumab Every Other Week |
|---|---|
| Crohn's DiseaseGastrointestinal disorders | 13/304 |
| small intestinal obstructionGastrointestinal disorders | 9/304 |
| abdominal abscessInfections and infestations | 4/304 |
| anaemiaBlood and lymphatic system disorders | 3/304 |
| abdominal painGastrointestinal disorders | 2/304 |
| subileusGastrointestinal disorders | 2/304 |
| heparin-induced thrombocytopeniaBlood and lymphatic system disorders | 1/304 |
| atroventricular block completeCardiac disorders | 1/304 |
| GI haemorrhageGastrointestinal disorders | 1/304 |
| GI motility disorderGastrointestinal disorders | 1/304 |
| Event | 40 mg Adalimumab Every Other Week |
|---|---|
| Crohn's DiseaseGastrointestinal disorders | 49/304 |
| Abdominal painGastrointestinal disorders | 23/304 |
| Injection site reactionGeneral disorders | 23/304 |
| NauseaGastrointestinal disorders | 19/304 |
| HeadacheNervous system disorders | 19/304 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 18/304 |
| NasopharyngitisInfections and infestations | 15/304 |
| FatigueGeneral disorders | 14/304 |
| Age, Categorical(Participants) | 40 mg Adalimumab Every Other Week |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 296 |
| >=65 years | 8 |
| Sex: Female, Male(Participants) | 40 mg Adalimumab Every Other Week |
|---|---|
| Female | 173 |
| Male | 131 |
| Race/Ethnicity, Customized(participants) | 40 mg Adalimumab Every Other Week |
|---|---|
| American Indian or Alaska Native | 2 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 291 |
| More than one race | 1 |
| Unknown or Not Reported | 6 |
| Hispanic | 0 |
| Region of Enrollment(Participants) | 40 mg Adalimumab Every Other Week |
|---|---|
| Canada | 304 |
| Alcohol(participants) | 40 mg Adalimumab Every Other Week |
|---|---|
| User | 147 |
| Ex-User | 15 |
| Non-User | 142 |
| C-Reactive protein mg/dL(participants) | 40 mg Adalimumab Every Other Week |
|---|---|
| < 1.0 mg/dL | 148 |
| > = 1.0 mg/dL | 155 |
| Missing | 1 |
| Nicotine(participants) | 40 mg Adalimumab Every Other Week |
|---|---|
| User | 98 |
| Ex-User | 84 |
| Non-User | 122 |
| Number Subjects With Draining Cutaneous Fistulas at Screening(participants) | 40 mg Adalimumab Every Other Week |
|---|---|
| Count 0 lesions | 235 |
| Count 1 lesion | 42 |
| Count 2 lesions | 16 |
| Count 3 lesions | 5 |
| Count >=4 lesions | 5 |
| Missing | 1 |
5 further baseline measures are reported on the registry.
The record gives a start of Jan 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2009, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab